PharmaGraphX

Log in Get Started

Nivolumab

Opdivo, Opdualag, Opdivo Qvantig

Monoclonal antibody

Standard

Half-life

26.7 days

Protein Binding

N/A

Metabolized By

N/A

External

Drugs.com

Clinical alerts

Nephrotoxic

Monitor renal function; avoid other nephrotoxins where possible

Hepatotoxic

Monitor liver function

Mechanism of action

Monoclonal antibody blocking PD-1 receptor on T cells

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Primary Mediastinal Large B-Cell Lymphoma
·Advanced Malignant Solid Neoplasm
·Metastatic Malignant Solid Neoplasm
·Unresectable Malignant Solid Neoplasm
·Stage II Nasopharyngeal Carcinoma AJCC v8

Interactions

No curated interaction pairs are recorded for Nivolumab. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Fatigue
Rash
Diarrhea
Immune-mediated adverse events

Pharmacokinetics

Published parameters · PMID:27226557

Half-life: 26.7 days
Protein binding: N/A
Clearance: 0.009 L/h; adult oncology patients (various solid tumors)
Volume of distribution: 7 L
Renally eliminated: 0%
Model: 1-compartment

Pregnancy & lactation

Not recorded for Nivolumab. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, published PK literature.

Not a substitute for clinical judgement